ClinicalTrials.gg
RecruitingNCT06013865SEKTRUpdated Nov 19, 2026

Empagliflozin Treatment in Kidney Transplant Recipients

A Phase 4 interventional study of Empagliflozin in Kidney Transplant and Chronic Kidney Disease, sponsored by VA Office of Research and Development. Recruiting at 5 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
264
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Planned enrollment
6th of 20
264 · median 77
Started
2024
with 4 others
Phase 4
9 of 20
5 open now
Registered
10th of 20
by date

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 6th largest by planned enrollment, is one of 5 that started in 2024, is one of 9 in phase 4, and was the 10th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.

Read the detailed description

Background: Kidney transplantation improves the health and quality of life for those veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.

Objective: The goal of this submission is to examine the safety and efficacy of SGLT2i therapy in Veterans with KTRs with and without T2DM. The hypothesis is treatment with SGLT2i will lead to improvements in graft and cardiovascular outcomes in patients with chronic kidney disease, with acceptable side effect profile.

Methods: To test this hypothesis, the investigators will execute a multicenter clinical trial at 5 VA medical centers, including 4 that serve as primary kidney transplant programs. The multidisciplinary research team includes transplant medical and surgical expertise, diabetology, and informatics and statistical support familiar with VA data systems. In open label fashion, the investigators will treat eligible KTRs and comprehensively assess adverse and serious adverse event data, as well as assess any untoward impacts on graft function and diabetes management. Secondly, the investigators will utilize VA data from the VINCI corporate data warehouse to develop a control cohort of Veterans with KTRs with and without T2DM, not treated with SGLT2i. The investigators will utilize propensity score matching to reduce bias that may occur in observational studies. With this strategy, the investigators will further address the potential beneficial impact of SGLT2i treatment on cardiovascular outcomes, as well as kidney disease progression in the transplanted kidney. The investigators will also analyze the cost impact of using this agent in this patient population, in terms of hospitalizations, unanticipated procedures, and CKD management.

Findings: These studies will provide new information to the transplant community for both Veteran and non-Veteran alike, with a detailed assessment of safety and feasibility of this agent class using a pragmatic approach to transplant care. These results will translate into an opportunity to mitigate late graft loss in this patient population, and a potential breakthrough in clinical care that to date has been unrecognized.

03

Conditions studied

  • Kidney Transplant
  • Chronic Kidney Disease

Keywords

  • Transplant
  • Diabetes
  • Kidney Failure
  • Rejection
  • Proteinuria
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (>18 years of age) male and female recipients (all races and ethnicities)
  2. Subject must be able to understand and provide consent
  3. Recipient of a primary or secondary kidney transplant at least 3 months or longer since transplant
  4. For subjects with T2DM or post-transplant diabetes (PTDM), measured kidney function by CKD epi must be 30mL/min/1.73m2 to 59 mL/min/1.73m2 or CKD epi eGFR 60 mL/min/1.73m2 with urinary albumin:creatinine ratio 30 mg/g (or protein:creatinine 100 mg/g).
  5. For subjects without T2DM or PTDM: measured kidney function by CKD epi eGFR must be 20mL/min/1.73m2 to 59mL/min/1.73m2 or CKD epi eGFR 60 mL/min/1.73m2 with urinary albumin:creatinine ratio 30 mg/g (or protein:creatinine 100 mg/g).

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness of a participant to give written or comply with study protocol
  2. History of prior pancreas transplant
  3. CKD epi \< 30 mL/min/1.73m2 for those with T2DM or \< 20 mL/min/1.73m2 for those without T2DM or anyone with 5mL/min/1.73m2 fall in eGFR per year
  4. Uncontrolled type 2 diabetes mellitus with most recent >12%
  5. History of >2 urinary tract infections per year or UTIs requiring admission in the last year, or urosepsis in the last year.
  6. Use of SGLT2i within 90 days
  7. Documented allergy to SGLT2i
  8. History of Type I diabetes mellitus
  9. History of diabetic ketoacidosis
  10. Indwelling foley catheter or urinary diversion
  11. Acute rejection in the prior 3 months
  12. Acute MACE event within 3 months of the study
  13. Severe congestive heart failure ( functional class III or higher)
  14. Active mucocutaneous mycotic infection of the groin or external genitalia.
  15. History of amputation due to peripheral vascular disease and/or diabetic foot ulcers within prior year
  16. History of except non-melanoma skin cancer within 2 years of screening
  17. Known of active current viral, fungal, mycobacterial, or other infections (including, but not limited to tuberculosis and atypical mycobacterial disease)
  18. infected subjects, including those who are well controlled on anti-retrovirals
  19. Recent (within 6 months) Positive Hep B PCR or active disease
  20. virus antibody positive (HCVAb+) subjects who have failed to demonstrate sustained viral remission for more than 12 weeks (after anti-viral treatment)
  21. Active pregnancy in a female transplant recipient
  22. A condition, in the eyes of the investigator, that precludes inclusion into the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Other
    Empagliflozin

    Open Label, Empagliflozin 12.5 mg QD

    Drug: Empagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Discontinuation of Empagliflozin

    The incidence of therapeutic discontinuation of empagliflozin in the kidney transplant recipient from time of initiation.

    Time frame: about 2 years

Secondary outcomes

  1. Infection

    Defined as the cumulative incidence of study defined Grade 3 or higher infection of the urinary tract or perineum after initiation of treatment.

    Time frame: about 2 years

  2. Hypoglycemia

    The cumulative incidence of grade 3 hypoglycemia

    Time frame: about 2 years

  3. Major cardiorenal events

    Time to first occurrence of the composite of major adverse cardiorenal events (MACER) as defined as all-cause mortality, stroke, non-fatal myocardial infarction, heart failure events including hospitalization for CHF or urgent CHF treatment, sustained (for at least 3 months) 40% decline in eGFR, or allograft failure as defined by chronic dialysis, re-transplantation, or persistent eGFR \<15mL/min/1.73m2)

    Time frame: about 2 years

  4. Acute Graft Dysfunction

    The cumulative incidence of \>15% elevation in serum creatinine for more than 4 weeks from the baseline defined prior to treatment.

    Time frame: about 2 years

  5. Volume Depletion

    The cumulative incidence of grade 3 volume depletion.

    Time frame: about 2 years

  6. Acute Cellular Rejection

    The cumulative incidence of acute rejection biopsy proven using 2017 criteria: Type IA Moderate tubulitis and at least moderate interstitial inflammation t2i2 or t2i3 Type IB Severe tubulitis and at least moderate interstitial inflammation t3i2 or t3i3 Type IIA Mild to moderate intimal arteritis v1 Type IIB Severe intimal arteritis (\> 25% of the luminal area) v2 Type III Transmural' arteritis and/or fibrinoid necrosis v3 Borderline: no intimal arteritis is present, t\>0 and i1 or i2/i3 and t1

    Time frame: about 2 years

  7. Amputation and foot ulceration

    The cumulative incidence of Grade 3 foot ulceration and/or need for amputation.

    Time frame: About 2 years

  8. Proteinuria

    Spot Urine Protein/creatinine ratio

    Time frame: 12 and 24 months

  9. Allograft Biopsy

    Time to incidence of a decline in eGFR sufficient to trigger a clinical decision for an allograft biopsy

    Time frame: about 2 years

  10. MACER

    Time to first occurrence of individual component of the MACER secondary outcome

    Time frame: about 2 years

  11. Death

    Time to the occurrence of cardiovascular death

    Time frame: about 2 years

  12. Acute graft dysfunction

    Time to acute kidney injury as defined as a \>15% change in eGFR from baseline

    Time frame: About 2 years

  13. Slope of kidney function

    Serum creatinine measured in mg/dL for all participants prior to treatment, at month 6, month 12 and month 24 of treatment.

    Time frame: over 2 years

  14. Glycemic Control

    Changes in Hemoglobin A1C over time of treatment

    Time frame: over 2 years

  15. Body Weight

    Change in body weight over time of treatment

    Time frame: over 2 years

  16. Blood Pressure

    Change in blood pressure measured in mmHg over the course of the study

    Time frame: over 2 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2030, 71 months after the start.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 71 months is above that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Aug 28, 2023
StartActual
Apr 5, 2024
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06013865
Collaborators
Iowa City VA Health Care System, VA Pittsburgh Healthcare System, VA Tennessee Valley Health Care System, VA Hines Health Care
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Apr 5, 2024
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Roslyn B Mannon, MD
Contact
roslyn.mannon@va.gov
(205) 999-7362
Ramesh K Ramalingam
Contact
Ramesh.Ramalingam@va.gov
(402) 995-4873
Roslyn B Mannon, MD
principal investigator · Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion